Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Elements in ‘Dark Genome’ Tied to Disease Progression Differences

Transposable elements, a common feature in the so-called “dark genome,” are associated with clinical differences in how Parkinson’s disease progresses among different people, a new study indicates. “Our main finding is that the presence or absence of [transposable elements] changes progression trajectory of [Parkinson’s], and we provided clinical, imaging,…

Gut Inflammation Helps Drive Disease, Mouse Study Indicates

In a mouse model of Parkinson’s disease animals show signs of inflammation in the gut, and treatment with cell therapies that reduce this inflammation help to ease symptoms of Parkinson’s, according to a new study. These results suggest that inflammatory conditions in the gut may contribute to the development…

FDA Clears NeuroOne Evo sEEG Device for Use Up to 30 Days

The U.S. Food and Drug Administration (FDA) has granted NeuroOne Medical Technologies clearance to market its Evo stereoelectroencephalography (sEEG) electrode technology for temporary use of less than 30 days. The device — previously cleared by the FDA for use of less than one day — is used to measure…

Human Embryonic Stem Cell Therapies Viewed Favorably: Survey

People with Parkinson’s disease have generally positive attitudes toward using therapies derived from human embryos, according to a new study based on interviews with patients in Sweden. The study, “Patients’ views on using human embryonic stem cells to treat Parkinson’s disease: an interview study,” was published in BMC Medical Ethics.

Neurorehabilitation Seen to Ease Disease Symptoms, Protect Neurons

A therapeutic mix of exercise, cognitive stimulation and social activity — known as environmental enrichment — eased Parkinson’s disease symptoms and protected brain cells in a mouse model, though to a greater extent in early disease stages, a study reported. Benefits were notably less potent in animals with more advanced…

Former Parkinson’s Caregivers Could Help Those Now in That Role

Former caregivers could serve as a helpful resource in supporting current caregivers of people with Parkinson’s disease, a study reported. The intent is to “provide guidance for developing peer-to-peer support programs, incorporating former carers,” its researchers wrote. The study, “Using former carers’ expertise in peer support for…

Potential Therapy FB-101 Well-tolerated in Healthy Volunteers

FB-101, an experimental oral therapy that 1ST Biotherapeutics is developing as a treatment for Parkinson’s disease, was well-tolerated in the first part of a Phase 1 clinical trial in healthy volunteers, the company announced. In the trial of (NCT04165837), which is being conducted in Baltimore,  24 adults…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums